Source: BEFREE ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF V600E mutation is a distinctive genomic alteration of pediatric low-grade gliomas with prognostic and therapeutic implications. 31667545

2020

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE BRAF V600E mutation is a distinctive genomic alteration of pediatric low-grade gliomas with prognostic and therapeutic implications. 31667545

2020

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Whereas both H3F3A K27M and BRAF V600E have been reported as poor prognostic markers in pediatric glioma, our case, along with several other reported cases, suggests that the coexistence of these two mutations might not indicate poor prognosis. 31254135

2019

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Whereas both H3F3A K27M and BRAF V600E have been reported as poor prognostic markers in pediatric glioma, our case, along with several other reported cases, suggests that the coexistence of these two mutations might not indicate poor prognosis. 31254135

2019

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF-V600E mutations are most commonly found in pleomorphic xanthoastrocytoma, ganglioglioma, epithelioid glioblastoma, and gliomas diagnosed at a younger age; BRAF-KIAA1549 fusion is the most common BRAF alteration in pilocytic astrocytoma. 30265855

2018

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Taken together with the facts that only one PXA preceded E-GBM among these lower-grade lesions, and that co-occurrence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions have been reported to be rare in conventional lower-grade diffuse gliomas, the diffuse glioma-like components may be distinct infiltrative components of E-GBM, reflecting intratumoral heterogeneity. 29105198

2018

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Additionally, BRAF V600E was only associated with a favorable prognosis in lower grade glioma. 28534272

2018

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE BRAF-V600E mutations are most commonly found in pleomorphic xanthoastrocytoma, ganglioglioma, epithelioid glioblastoma, and gliomas diagnosed at a younger age; BRAF-KIAA1549 fusion is the most common BRAF alteration in pilocytic astrocytoma. 30265855

2018

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Taken together with the facts that only one PXA preceded E-GBM among these lower-grade lesions, and that co-occurrence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions have been reported to be rare in conventional lower-grade diffuse gliomas, the diffuse glioma-like components may be distinct infiltrative components of E-GBM, reflecting intratumoral heterogeneity. 29105198

2018

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Additionally, BRAF V600E was only associated with a favorable prognosis in lower grade glioma. 28534272

2018

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation. 28062673

2017

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. 28727518

2017

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. 28727518

2017

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE We were unable to find other examples of glial tumors in public databases with this rare BRAF V600D mutation. 27860162

2017

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation. 28062673

2017

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. 26384810

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE These findings are consistent with clonal expansion of a morphologically distinct focus, harboring a private BRAF V600E mutation within an IDH1-mutant glioma. 26414224

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes. 27350555

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE We discuss differential diagnosis of the tumor, and review previously described diffuse gliomas with the BRAF V600E mutation. 26445861

2016

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE These findings are consistent with clonal expansion of a morphologically distinct focus, harboring a private BRAF V600E mutation within an IDH1-mutant glioma. 26414224

2016

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. 26384810

2016

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE We discuss differential diagnosis of the tumor, and review previously described diffuse gliomas with the BRAF V600E mutation. 26445861

2016

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes. 27350555

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE We demonstrated that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with BRAF(V</span>600E</span>) in</span>hibitor PLX4720 to reduce MAPK and Akt signaling, resulting in decreased glioma cell viability. 26023796

2015

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade glial tumors with neuronal component or differentiation. 25346165

2015